Gastrointestinal	gastrointestinal	O	O	O	O
tolerability	tolerability	O	O	O	O
of	of	O	O	O	O
etoricoxib	etoricoxib	O	O	OTHERS	I
in	in	O	O	O	O
rheumatoid	rheumatoid	O	DISEASE	OTHERS	I
arthritis	arthritis	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
:	:	O	O	O	O
results	results	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
etoricoxib	etoricoxib	O	O	OTHERS	I
vs	vs	O	O	O	O
diclofenac	diclofenac	CHEMICALS	O	OTHERS	I
sodium	sodium	CHEMICALS	O	OTHERS	I
gastrointestinal	gastrointestinal	O	O	O	O
tolerability	tolerability	O	O	O	O
and	and	O	O	O	O
effectiveness	effectiveness	O	O	O	O
trial	trial	O	O	O	O
(EDGE-II).OBJECTIVE	(edge-ii).objective	O	O	O	O
:	:	O	O	O	O
A	a	O	O	O	O
randomised	randomised	O	O	O	O
,	,	O	O	O	O
double-blind	double-blind	O	O	O	O
study	study	O	O	O	O
to	to	O	O	O	O
compare	compare	O	O	O	O
the	the	O	O	O	O
gastrointestinal	gastrointestinal	O	O	O	O
(	(	O	O	O	O
GI	gi	O	O	O	O
)	)	O	O	O	O
tolerability	tolerability	O	O	O	O
,	,	O	O	O	O
safety	safety	O	O	O	O
and	and	O	O	O	O
efficacy	efficacy	O	O	O	O
of	of	O	O	O	O
etoricoxib	etoricoxib	O	O	OTHERS	I
and	and	O	O	O	O
diclofenac	diclofenac	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
rheumatoid	rheumatoid	O	DISEASE	OTHERS	I
arthritis	arthritis	O	DISEASE	OTHERS	I
(	(	O	O	O	O
RA	ra	O	O	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

PATIENTS	patients	O	O	O	O
AND	and	O	O	O	O
METHODS	methods	O	O	O	O
:	:	O	O	O	O
A	a	O	O	O	O
total	total	O	O	O	O
of	of	O	O	O	O
4086	4086	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
mean	mean	O	O	O	O
age	age	O	O	O	O
60.8	60.8	O	O	O	O
years	years	O	O	O	O
)	)	O	O	O	O
diagnosed	diagnosed	O	O	O	O
with	with	O	O	O	O
RA	ra	O	O	OTHERS	I
were	were	O	O	O	O
enrolled	enrolled	O	O	O	O
and	and	O	O	O	O
received	received	O	O	O	O
etoricoxib	etoricoxib	O	O	OTHERS	I
90	90	O	O	O	O
mg	mg	O	O	OTHERS	I
daily	daily	O	O	O	O
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
2032	2032	O	O	O	O
)	)	O	O	O	O
or	or	O	O	O	O
diclofenac	diclofenac	CHEMICALS	O	OTHERS	I
75	75	O	O	O	O
mg	mg	O	O	OTHERS	I
twice	twice	O	O	O	O
daily	daily	O	O	O	O
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
2054	2054	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Use	use	O	O	O	O
of	of	O	O	O	O
gastroprotective	gastroprotective	O	O	O	O
agents	agents	O	O	O	O
and	and	O	O	O	O
low-dose	low-dose	O	O	O	O
aspirin	aspirin	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
allowed	allowed	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
prespecified	prespecified	O	O	O	O
primary	primary	O	O	O	O
end	end	O	O	O	O
point	point	O	O	O	O
consisted	consisted	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
cumulative	cumulative	O	O	O	O
rate	rate	O	O	O	O
of	of	O	O	O	O
patient	patient	O	O	O	O
discontinuations	discontinuations	O	O	O	O
due	due	O	O	O	O
to	to	O	O	O	O
clinical	clinical	O	O	O	O
and	and	O	O	O	O
laboratory	laboratory	O	O	O	O
GI	gi	O	O	O	O
adverse	adverse	O	O	O	O
experiences	experiences	O	O	O	O
(	(	O	O	O	O
AEs	aes	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

General	general	O	O	O	O
safety	safety	O	O	O	O
was	was	O	O	O	O
also	also	O	O	O	O
assessed	assessed	O	O	O	O
,	,	O	O	O	O
including	including	O	O	O	O
adjudicated	adjudicated	O	O	O	O
thrombotic	thrombotic	O	DISEASE	OTHERS	I
cardiovascular	cardiovascular	O	O	OTHERS	I
event	event	O	O	O	O
data	data	O	O	O	O
.	.	O	O	O	O

Efficacy	efficacy	O	O	O	O
was	was	O	O	O	O
evaluated	evaluated	O	O	O	O
using	using	O	O	O	O
the	the	O	O	O	O
Patient	patient	O	O	O	O
Global	global	O	O	O	O
Assessment	assessment	O	O	O	O
of	of	O	O	O	O
Disease	disease	O	O	O	O
Status	status	O	O	O	O
(	(	O	O	O	O
PGADS	pgads	O	O	O	O
;	;	O	O	O	O
0	0	O	O	O	O
-	-	O	O	O	O
4	4	O	O	O	O
point	point	O	O	O	O
scale	scale	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Mean	mean	O	O	O	O
(	(	O	O	O	O
SD	sd	O	O	OTHERS	I
;	;	O	O	O	O
maximum	maximum	O	O	O	O
)	)	O	O	O	O
duration	duration	O	O	O	O
of	of	O	O	O	O
treatment	treatment	O	O	O	O
was	was	O	O	O	O
19.3	19.3	O	O	O	O
(	(	O	O	O	O
10.3	10.3	O	O	O	O
;	;	O	O	O	O
32.9	32.9	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
19.1	19.1	O	O	O	O
(	(	O	O	O	O
10.4	10.4	O	O	O	O
;	;	O	O	O	O
33.1	33.1	O	O	O	O
)	)	O	O	O	O
months	months	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
etoricoxib	etoricoxib	O	O	OTHERS	I
and	and	O	O	O	O
diclofenac	diclofenac	CHEMICALS	O	OTHERS	I
groups	groups	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
cumulative	cumulative	O	O	O	O
discontinuation	discontinuation	O	O	O	O
rate	rate	O	O	O	O
due	due	O	O	O	O
to	to	O	O	O	O
GI	gi	O	O	OTHERS	I
AEs	aes	O	O	OTHERS	I
was	was	O	O	O	O
significantly	significantly	O	O	O	O
lower	lower	O	O	O	O
with	with	O	O	O	O
etoricoxib	etoricoxib	O	O	OTHERS	I
than	than	O	O	O	O
diclofenac	diclofenac	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
5.2	5.2	O	O	O	O
vs	vs	O	O	O	O
8.5	8.5	O	O	O	O
events	events	O	O	O	O
per	per	O	O	O	O
100	100	O	O	O	O
patient-years	patient-years	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
;	;	O	O	O	O
hazard	hazard	O	O	O	O
ratio	ratio	O	O	O	O
0.62	0.62	O	O	O	O
(	(	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
:	:	O	O	O	O
0.47	0.47	O	O	O	O
,	,	O	O	O	O
0.81	0.81	O	O	O	O
;	;	O	O	O	O
p	p	O	O	OTHERS	I
<	<	O	O	O	O
or=0.001	or=0.001	O	O	O	O
)	)	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
discontinuations	discontinuations	O	O	O	O
for	for	O	O	O	O
hypertension-related	hypertension-related	O	O	O	O
and	and	O	O	O	O
oedema-related	oedema-related	O	O	O	O
AEs	aes	O	O	O	O
were	were	O	O	O	O
significantly	significantly	O	O	O	O
higher	higher	O	O	O	O
with	with	O	O	O	O
etoricoxib	etoricoxib	O	O	OTHERS	I
(	(	O	O	O	O
2.5	2.5	O	O	O	O
%	%	O	O	O	O
and	and	O	O	O	O
1.1	1.1	O	O	O	O
%	%	O	O	O	O
respectively	respectively	O	O	O	O
)	)	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
diclofenac	diclofenac	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
1.5	1.5	O	O	O	O
%	%	O	O	O	O
and	and	O	O	O	O
0.4	0.4	O	O	O	O
%	%	O	O	O	O
respectively	respectively	O	O	O	O
;	;	O	O	O	O
p<0.001	p<0.001	O	O	O	O
for	for	O	O	O	O
hypertension	hypertension	O	DISEASE	OTHERS	I
and	and	O	O	O	O
p<0.01	p<0.01	O	O	O	O
for	for	O	O	O	O
oedema	oedema	O	O	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

Etoricoxib	etoricoxib	O	O	OTHERS	I
and	and	O	O	O	O
diclofenac	diclofenac	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
resulted	resulted	O	O	O	O
in	in	O	O	O	O
similar	similar	O	O	O	O
efficacy	efficacy	O	O	O	O
(	(	O	O	O	O
PGADS	pgads	O	O	O	O
mean	mean	O	O	O	O
changes	changes	O	O	O	O
from	from	O	O	O	O
baseline	baseline	O	O	O	O
-0.62	-0.62	O	O	O	O
vs	vs	O	O	O	O
-0.58	-0.58	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
Etoricoxib	etoricoxib	O	O	OTHERS	I
90	90	O	O	O	O
mg	mg	O	O	OTHERS	I
demonstrated	demonstrated	O	O	O	O
a	a	O	O	O	O
significantly	significantly	O	O	O	O
lower	lower	O	O	O	O
risk	risk	O	O	O	O
for	for	O	O	O	O
discontinuing	discontinuing	O	O	O	O
treatment	treatment	O	O	O	O
due	due	O	O	O	O
to	to	O	O	O	O
GI	gi	O	O	OTHERS	I
AEs	aes	O	O	OTHERS	I
compared	compared	O	O	O	O
with	with	O	O	O	O
diclofenac	diclofenac	CHEMICALS	O	OTHERS	I
150	150	O	O	O	O
mg	mg	O	O	OTHERS	I
.	.	O	O	O	O

Discontinuations	discontinuations	O	O	O	O
from	from	O	O	O	O
renovascular	renovascular	O	O	O	O
AEs	aes	O	O	O	O
,	,	O	O	O	O
although	although	O	O	O	O
less	less	O	O	O	O
common	common	O	O	O	O
than	than	O	O	O	O
discontinuations	discontinuations	O	O	O	O
from	from	O	O	O	O
GI	gi	O	O	OTHERS	I
AEs	aes	O	O	OTHERS	I
,	,	O	O	O	O
were	were	O	O	O	O
significantly	significantly	O	O	O	O
higher	higher	O	O	O	O
with	with	O	O	O	O
etoricoxib	etoricoxib	O	O	OTHERS	I
.	.	O	O	O	O

